2018
Treatment with epigenetic agents profoundly inhibits tumor growth in leiomyosarcoma
De Carvalho Fischer C, Hu Y, Morreale M, Lin WY, Wali A, Thakar M, Karunasena E, Sen R, Cai Y, Murphy L, Zahnow CA, Keer H, Thakar M, Ahuja N. Treatment with epigenetic agents profoundly inhibits tumor growth in leiomyosarcoma. Oncotarget 2018, 9: 19379-19395. PMID: 29721210, PMCID: PMC5922404, DOI: 10.18632/oncotarget.25056.Peer-Reviewed Original ResearchDNA methyltransferase inhibitorEpigenetic modulatorsLMS cell linesCell linesMES-SAApoptotic pathwayCell cycleMethyltransferase inhibitorCell survivalDifferentiation patternsEpigenetic agentsNovel chemotherapeutic regimensPotential therapeutic applicationsLeiomyosarcoma cell lineRare mesenchymal neoplasmSpectrum of sensitivityChemotherapeutic regimensPoor prognosisMesenchymal neoplasmsSensitive linesTumor growthGuadecitabineTherapeutic applicationsAdditional studiesModulator
2015
Epigenetic therapy for solid tumors: from bench science to clinical trials
Juo YY, Gong XJ, Mishra A, Cui X, Baylin SB, Azad NS, Ahuja N. Epigenetic therapy for solid tumors: from bench science to clinical trials. Epigenomics 2015, 7: 215-235. PMID: 25942532, DOI: 10.2217/epi.14.73.Peer-Reviewed Original ResearchConceptsEpigenetic agentsCpG island promotersSolid tumorsGlobal DNA methylationOptimal patient selectionTumor suppressor geneNew therapeutic modalitiesChromatin changesCancer epigenomeHistone deacetylase inhibitorsDNA methylationDNA methyltransferaseEpigenetic therapyHormonal therapyDrug regimenSuppressor genePatient selectionFuture trialsHematologic malignanciesRecent trialsClinical trialsSignificant efficacyTherapeutic modalitiesPhenotype changesDeacetylase inhibitors